Presence of Nitrosamines, which are probable human carcinogens, has been an evolving challenge facing the pharmaceutical industry. Regulators became first aware of this impurity in mid – 2018, when NDMA was found in blood pressure medicine known as sartans. Ever since, the pharmaceutical industry has been working hard to mitigate the formation of Nitrosamines Impurities.
With the extensive research conducted by us, we have identified certain key challenges around nitrosamine formation, faced by the pharma manufacturers. We bring to you “Nitrosamine Advance Workshop 2024” where we have experts from across the industry sharing their experience and expertise gained in this evolving concern. This workshop provides a comprehensive and in-depth exploration of nitrosamines, covering both updated regulatory guidelines and analytical understanding, and allowing participants to engage in practical discussions, case study solving sessions and hands-on learning experience.
Join us to network with your industry peers and experts, discuss your challenges and get some practical solutions.
